(Total Views: 119)
Posted On: 06/27/2024 9:09:30 AM
Post# of 102282
You guys gotta see this one, about to be a NASDAQ - Ready to run triple digit gains IMO. This is a great example of what the future of medtech looks like.
New Growth Report BioStem Technologies, Inc. (BSEM)
BSEM Key Highlights
Completed an extensive two-year audit in preparation for moving BSEM to a national exchange. (NASDAQ or NYSE)
Recently released their Q1 earnings, which shocked the market with revenues totaling $41 million in the first quarter of 2024.
First positive net income of over $4.4 million in the quarter.
Analyst Target $23.75 representing a 153% upside from the current price of $9.38
Regenerative medicine leverages the body's natural systems to rebuild tissues and organs. It is expected to revolutionize healthcare, with the global stem cell market projected to reach $18.4 billion by 2028.
Take a minute to look at the full analysis >>> https://broadstreetalerts.com/wp-content/uplo...6-27-24.pd
New Growth Report BioStem Technologies, Inc. (BSEM)
BSEM Key Highlights
Completed an extensive two-year audit in preparation for moving BSEM to a national exchange. (NASDAQ or NYSE)
Recently released their Q1 earnings, which shocked the market with revenues totaling $41 million in the first quarter of 2024.
First positive net income of over $4.4 million in the quarter.
Analyst Target $23.75 representing a 153% upside from the current price of $9.38
Regenerative medicine leverages the body's natural systems to rebuild tissues and organs. It is expected to revolutionize healthcare, with the global stem cell market projected to reach $18.4 billion by 2028.
Take a minute to look at the full analysis >>> https://broadstreetalerts.com/wp-content/uplo...6-27-24.pd
(0)
(0)Scroll down for more posts ▼
